TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Sunshine Biopharma ( (SBFM) ) is now available.
Sunshine Biopharma Inc. announced the successful closing of a $2.46 million registered direct offering with institutional investors, involving the sale of shares of Common Stock and pre-funded warrants. The proceeds from this offering will be used for general corporate purposes and working capital, potentially enhancing the company’s operational capabilities and market positioning. Aegis Capital Corp. acted as the exclusive placement agent for the offering, which was conducted under an effective shelf registration statement filed with the SEC.
More about Sunshine Biopharma
Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines across various therapeutic areas, including oncology and antivirals. The company has 70 generic prescription drugs available in Canada and plans to launch 13 additional drugs in 2025, including NIOPEG®, a biosimilar of NEULASTA®. Sunshine Biopharma is also developing proprietary drugs such as K1.1 mRNA for liver cancer and PLpro protease inhibitor for SARS Coronavirus infections.
YTD Price Performance: -28.12%
Average Trading Volume: 1,210,546
Technical Sentiment Signal: Strong Buy
Current Market Cap: $5.63M
For detailed information about SBFM stock, go to TipRanks’ Stock Analysis page.